Citadel Advisors
ABOS icon

Citadel Advisors’s Acumen Pharmaceuticals ABOS Stock Holding History

Citadel Advisors’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-345,283
Closed -$881K – 12862
2025
Q4 		$729K Sell
345,283
-148,825
-30% -$295K ﹤0.01% 8122
2025
Q3 		$845K Buy
+494,108
New +$684K ﹤0.01% 7907
2025
Q1 		– Sell
-9,597
Closed -$13.7K – 14363
2024
Q4 		$16.5K Sell
9,597
-7,315
-43% -$17.6K ﹤0.01% 13299
2024
Q3 		$41.9K Sell
16,912
-66,100
-80% -$179K ﹤0.01% 12098
2024
Q2 		$201K Buy
83,012
+59,661
+255% +$190K ﹤0.01% 9934
2024
Q1 		$94.6K Sell
23,351
-107,765
-82% -$406K ﹤0.01% 11438
2023
Q4 		$503K Buy
131,116
+130,884
+56,416% +$389K ﹤0.01% 8094
2023
Q3 		$963 Sell
232
-47,162
-100% -$291K ﹤0.01% 13945
2023
Q2 		$228K Buy
47,394
+33,313
+237% +$159K ﹤0.01% 9592
2023
Q1 		$57.2K Buy
+14,081
New +$73.5K ﹤0.01% 11991
2022
Q3 		– Sell
-53,749
Closed -$308K – 12480
2022
Q2 		$253K Sell
53,749
-99,498
-65% -$374K ﹤0.01% 10188
2022
Q1 		$599K Buy
153,247
+78,724
+106% +$428K ﹤0.01% 8959
2021
Q4 		$504K Buy
74,523
+35,177
+89% +$387K ﹤0.01% 9681
2021
Q3 		$585K Buy
+39,346
New +$655K ﹤0.01% 9481

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Citadel Advisors's ABOS Position: Q1 2026 in Review

Citadel Advisors sold out of Acumen Pharmaceuticals (ABOS) in Q1 2026, closing a stake of 345,283 shares — an estimated $881K sold.

Citadel Advisors first reported a position in ABOS in Q3 2021 and held it in 14 quarters. The position peaked at $845K in Q3 2025. 84 funds tracked by Wall St. Rank hold ABOS as of Q1 2026.

  • Citadel Advisors reported no remaining Acumen Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 345,283 Acumen Pharmaceuticals shares in Q1 2026, an estimated $881K.
  • Citadel Advisors first reported a position in Acumen Pharmaceuticals in Q3 2021 and held it in 14 quarters.
  • Citadel Advisors's Acumen Pharmaceuticals position peaked at $845K in Q3 2025.
  • 84 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.